Intravitreal Bevacizumab for Retinopathy of Prematurity: Another Hit to the Immature Lung?

Chest. 2022 Dec;162(6):1231-1232. doi: 10.1016/j.chest.2022.06.032.

Authors

Ignacio Oulego-Erroz¹, Almudena Alonso-Ojembarrena²

Affiliations

¹ Pediatric and Neonatal Intensive Care Unit, Complejo Asistencial Universitario de Leon and the University of León Institute of Biomedicine, León, Spain. Electronic address: ignacio.oulego@gmail.com.
² Neonatal Intensive Care Unit, Hospital Universitario Puerta del Mar, and the Biomedical Research and Innovation Institute of Cádiz (INiBICA). Research Unit, Puerta del Mar University Hospital, Cádiz, Spain.

PMID: 36494122
DOI: 10.1016/j.chest.2022.06.032

No abstract available

Publication types

Editorial

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Bevacizumab / therapeutic use
Gestational Age
Humans
Infant, Newborn
Infant, Premature*
Lung
Retinopathy of Prematurity* / drug therapy

Substances

Bevacizumab
Antibodies, Monoclonal, Humanized
Angiogenesis Inhibitors